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ABSTRACT
Objective: To conduct a cross-national validation of the Scales for Out-
comes in Parkinson’s Disease-PsychoSocial questionnaire (SCOPA-PS) in
four Latin American Countries.
Methods: Data quality (missing items), scale assumptions (item–test cor-
relation), internal consistency (Cronbach’s alpha, item homogeneity),
factor structure, content validity, and precision (standard error of mea-
surement, SEM) of the scale were explored, as was convergent validity
with motor symptoms (Clinical Impression of Severity Index [CISI-PD],
Scales for Outcomes in Parkinson’s Disease-Motor Scale), emotional
status (Hospital Anxiety and Depression Scale) and health-related quality
of life (Parkinson Disease Questionnaire-39). Known-groups validity was
studied by category of severity, based on Hoehn and Yahr staging (HY),
CISI-PD, and disease duration.
Results: Three hundred thirty-one Parkinson’s disease (PD) patients with
usable data participated (mean age 64.7 years; 42.3% female; mean PD
duration 8.5 years; HY, 1 to 5). Data quality (missing items <10%),
scale assumptions (item–total correlation = 0.43 - 0.71) and internal
consistency of SCOPA-PS (Cronbach’s alpha = 0.87; item homogene-
ity = 0.38) were satisfactory. Factor analysis suggested a unifactorial
structure. High convergent validity was found for depression (rS = 0.61),
anxiety (rS = 0.62), and health-related quality of life (rS = 0.82). Known-
groups validity analyses indicated a gradual inﬂuence of severity cat-
egory and disease duration on SCOPA-PS scores (P < 0.0001). SEM
value was 8.24 (7 to 12 in previous studies). These magnitudes may be
indicative of the threshold for a real change and a minimum important
difference.
Conclusions: The Latin American versions of the SCOPA-PS displayed
appropriate psychometric attributes.
Keywords: CISI-PD, health-related quality of life, Parkinson’s disease,
PDQ-39, SCOPA-PS.
Introduction
A progressive neurologic disease affecting approximately 2% of
the population aged 65 years and over, Parkinson’s disease (PD)
ranks as the second leading neurodegenerative and one of the
most burdensome diseases [1,2]. Over the last few years, greater
attention has been devoted to nonmotor symptoms of PD. Psy-
chological nonmotor symptoms including depression, apathy,
social embarrassment, loneliness, and increasing dependence on
others for everyday activities have scarcely been addressed in the
literature. There is evidence to suggest that in addition to the
motor disorder, the psychological manifestations of PD are major
factors accounting for disability and deterioration in quality of
life. For instance, low self-reported satisfaction with social
support is linked to higher depression, anxiety, and stress among
PD patients [3]. In addition, depression is the strongest determi-
nant of health-related quality of life (HRQoL) in PD patients [4].
In this connection, experts have acknowledged the need for spe-
ciﬁc instruments to measure PD’s psychosocial outcomes and
HRQoL [5,6].
A recent review by Dowding and Claire [7] concluded that
the lack of uniformity in the choice of HRQoL tools used in PD
studies renders comparison of results difﬁcult. Furthermore, the
few studies available have been undertaken in developed nations,
meaning that there are almost no assessment tools validated for
Asia, Africa, or South America [8,9].
This study presents a cross-cultural adaptation and multina-
tional validation of the Scales for Outcomes in Parkinson’s
Disease-Psychosocial Questionnaire (SCOPA-PS) [10] in four
Latin American countries (Argentina, Brazil, Ecuador, and Para-
guay). The designated goals of this study were: 1) to obtain a
cross-culturally adapted version of the SCOPA-PS for all partici-
pant countries; and 2) to analyze the psychometric properties of
the scale in a wide multinational sample, including some speciﬁc
analyses per country.
Patients and Methods
Patients
The sample was composed of consecutive PD outpatients from
the participant centers. Patients were assessed in the period from
March through August 2006. Inclusion criteria were: diagnosis
of PD as per the UK Parkinson’s Disease Society Brain Bank
Criteria [11], age 30 years or over at disease onset, and Hoehn
and Yahr stages (HY) 1 to 5 [12]. Exclusion criteria were: 1)
parkinsonism other than PD; 2) concomitant severe condition,
acute disorder or injury, pharmacological effect (e.g., dopamine
antagonists), sensorial deﬁcit (e.g., blindness), or sequela status
(e.g., hemiplegia) potentially interfering with evaluation of PD
manifestations and impact; 3) inability to read or understand
questionnaires; and 4) refusal to participate. The local Institu-
tional Review Board at every participating center approved the
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study protocol. Informed consent in accordance with local
ethical guidelines was obtained from all participants.
Assessments
In addition to the standard PD evaluation measures, a sociode-
mographic questionnaire, the SCOPA-PS, and additional instru-
ments for validity analysis purposes were administered to all
participants. HY and the Clinical Impression of Severity Index
(CISI-PD) [13] were used to determine PD stage and global
severity, respectively. Motor aspects were appraised by means of
the Scales for Outcomes in Parkinson’s Disease-Motor Scale
(SCOPA-MS) [14]. The Cumulative Illness Rating Scale Geriatric
version (CIRS-G) [15] was applied to assess comorbidity. In
addition, the Hospital Anxiety and Depression Scale (HADS)
[16] was used for anxiety and depression screening. HRQoL was
assessed by means of the Parkinson Disease Questionnaire-39
(PDQ-39) [17,18].
HY staging encompasses ﬁve stages of growing severity, from
HY 1 (unilateral symptoms) to HY 5 (wheelchair or bed-bound).
In this study, the original HY [12] was used and severity levels
were collapsed into the following three major categories: mild
(stages 1 and 2), moderate (stage 3), and severe (stages 4 and 5).
The CISI-PD assesses clinical impression of severity with
respect to four items, namely, motor signs, disability, motor
complications, and cognitive status. Each item is scored on a
seven-point Likert scale (from 0, normal, to 6, very severe), and
the total score is reached by summing all four items. For validity
study purposes, the scale rangewas split into three severity groups,
mild (1–7), moderate (8–14), and severe (15).
The PDQ-39 is a self-administered 39-item scale. Items refer
to self-reported difﬁculty in respect of each item during the
previous month. Items are scored on a ﬁve-point Likert scale,
with higher scores indicating greater difﬁculty (0: never to 4:
always). The questionnaire is made up of eight dimensions:
mobility (10 items), activities of daily living (six items), emo-
tional well-being (six items), stigma (four items), social support
(three items), cognition (four items), communication (three
items), and bodily discomfort (three items). For each domain, the
summed item scores are transformed into a percentage of the
maximum possible total score. The PDQ-39 summary index (SI)
is the sum obtained from the sum of all such domain scores
divided by the number of domains.
The SCOPA-MS is a 21-item scale covering three domains,
i.e., motor examination (10 items), activities of daily living
(ADL) (seven items), and motor complications (four items). All
items are scored on a four-point Likert scale (0: normal; 3:
severe). Total scores are obtained by summing item scores: the
higher the score, the more severe the motor disorder.
The CIRS-Gwas used to assess comorbidity. CIRS-Gmeasures
the severity of simultaneous diseases in 14 organ systems, and is
administered by a physician. Items are answered on a four-point
Likert scale (0: none; 4: extremely severe—immediate treatment
required/end organ failure/severe impairment in function), with
the total score being the result of summing the individual item
scores. The CIRS-G has been successfully used to assess comor-
bidity in PD patients [19].
The strong association between depression/anxiety and PD
justiﬁed HADS administration [20]. This scale comprises 14
items, 7 addressing anxiety and 7 depression. Items are answered
on a four-point Likert scale (0: no problem; 3: severe problem).
Anxiety and depression scores (HADS-Anx, HADS-Dep) are
computed by summing the items in each construct. Eleven or
more points on either of the two subscales is evidence of clinically
signiﬁcant levels of anxiety or depression [21].
The SCOPA-PS is a self-administered, 11-item questionnaire
assessing psychosocial functioning during the preceding month.
Items are scored on a four-point Likert scale, with higher scores
denoting greater difﬁculty (0: not at all; 3: very much). The
summary index—used for analysis purposes in this study—is
obtained by summing up direct item scores transformed into
percentage values. Previous validation studies have proved satis-
factory [8,10].
Translation and Back-Translation
The original English-language version [10] was adapted to
Spanish as follows: two bilingual contributors agreed on a
Spanish version based on the original English questionnaire. A
panel of experts reviewed and revised the Spanish version until
agreement was reached on its linguistic and conceptual equiva-
lence vis-à-vis the original. Both original English and Spanish
version were then forwarded to the Latin American coresearchers,
who proceeded to adjust the instrument to the local Spanish,
Portuguese, and Guarani languages. Back-translations from local
versions into Spanish (Spain) were subsequently sent to coauthor
PMM, and revised until considered equivalent.
Analyses
Data quality and acceptability were determined by percentage of
missing data per item (criterion <10%) and fully computable
scores (criterion >90%) [22], difference between observed and
possible scores, mean to median differences (suggested criterion
<15% maximum score), ceiling and ﬂoor effects (criterion <15%)
[23], skewness (criterion -1 to +1) [24], and kurtosis (criterion
-1 to +1) [25].
Item–total correlation corrected for overlap (criterion
r  0.30) [26] was calculated to substantiate scaling assump-
tions. Internal consistency was explored by means of Cronbach’s
alpha (criterion 0.70) [27] and item homogeneity index (mean
of interitem correlation; criterion >0.30) [28]. The content valid-
ity index was determined by the proportion of experts in a panel,
who rated the scale as representative and relevant to the con-
struct being measured. A letter with the scale and assessment
materials was forwarded to 10 experts. Experts were asked to
rate the SCOPA-PS items on a four-point Likert scale (1: not
relevant; 4: very relevant and concise). The content validity index
is the proportion of items rated as 3 or 4 by the board of experts
(criterion 75%) [29,30].
Exploratory factor analysis was performed using the princi-
pal components method. Adequacy of the correlation matrix was
studied by reference to Bartlett’s statistic (criterion: P  0.05)
and the Kaiser-Meyer-Olkin criterion (KMO; criterion 0.5)
test. Explained variance of dimensions with eigenvalues of over 1
was explored. Parallel analysis was used to determine the number
of dimensions retained [31]. Loading per item and reliability
estimates [32] (suggested criterion: 0.80) of the resulting
matrix were obtained. Finally, mean ﬁtted residuals (criterion
<1 n ) and the root mean square residuals (RMSR) (criterion
<0.06) were analyzed. Factor analysis was performed using the
Factor statistical package [33].
Convergent validity was estimated by correlating SCOPA-PS
with another HRQoL measure (PDQ-39), PD-symptom scales
(SCOPA-MS, CISI-PD), anxiety and depression (HADS), and
disease stage (HY) and duration. We hypothesized that
SCOPA-PS correlation would be high (rS  0.60) as against
PDQ-39 and HADS, and moderate as against SCOPA-MS, CISI-
PD, disease severity (categories based on HY) and with disease
duration (rS = 0.30 - 0.59). Given that variables were nonnor-
mally distributed, Spearman’s rank correlation coefﬁcient was
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used. Fisher’s Z statistic was used to compare correlation coef-
ﬁcients in per-country convergent validity analyses.
Known-groups validity analyses entailed breaking down
SCOPA-PS scores by HY and CISI-PD severity level, and cat-
egory of disease duration (<5 y., 5–9 years, 10 years).
A stepwise regression analysis model was constructed in
order to identify the association between sociodemographic and
disease-related factors and psychosocial functioning in PD. In
order to avoid colinearity, correlation coefﬁcients higher than
0.40 between independent variables within a model were not
permitted. In the latter case, alternative regression models were
calculated separately for both independent variables.
The standard error of measurement for a single observed
score (standard error of the mean SEM SD[ ] = −1 α ) [34]
and its 95% upper conﬁdence limit (1.96 ¥ SEM) [23] were
calculated in order to assess the precision of the assessed scale
(suggested criterion: SEM  SD/2) [35].
In addition to the analysis in the pooled sample, major psy-
chometric attributes (internal consistency, precision, and conver-
gent validity) were explored by country.
Results
A sample of 338 participants met the inclusion criteria. For
analysis purposes, an individual’s mean was used to impute one
missing SCOPA-PS value [36], and seven patients with two or
more missing values were not included. Consequently, the data
referred to a total of 331 patients (42.30% female; mean
age  SD: 64.68  10.76 y.). Mean disease duration at the date
of assessment was 8.45  6.04 (range: 0–43), and median HY
was 3.0 (interquartile range: 2–3) (Table 1).
SCOPA-PS item 5 (sexuality) registered 69 missing values, 46
corresponding to single, widowed, and divorced participants.
Hence, item 5 was missing in only 9.87% of married partici-
pants. The proportion of missing values for the remaining
SCOPA-PS items was 0.59% to 2.07%. The observed scoring
range covered the possible range for all items and for the total
score. Neither ﬂoor nor ceiling effects were observed (0.91%);
skewness was 0.39 and kurtosis -0.49. Item–total correlation
coefﬁcients ranged from 0.43 (item 10) to 0.71 (item 9). Data
quality, acceptability, and scale assumptions estimates are shown
in Table 2.
Cronbach’s alpha was 0.87 and item homogeneity index,
0.38. Table 3 shows the internal consistency estimates per
country. Although estimates were numerically similar for all
countries, they were nonetheless slightly higher for the Argentine
sample (0.92; 0.49, respectively). Content validity index for the
SCOPA-PS was 92.93% (panel response rate 90%). Qualitative
assessment by the panel of experts raised a few minor drafting
issues including: 1) polysemic use of the Spanish verb “relacio-
narse” in the items 3, 4, and 5 that may involve redundancy and
lack of clarity; 2) emotional effect of the test in the respondent
given the negative valence of most items; and 3) item 1 may be
not applicable to all patients as some of them have no household
or work duties assigned.
In view of the nonnormally distributed data (Kolmogorov-
Smirnov test, P < 0.01) and item kurtosis (Table 2), a principal
components factor analysis based on polychoric correlations was
conducted [37]. The KMO statistic exceeded 0.5 (KMO =
0.904), and Bartlett’s test was signiﬁcant (c255 = 1587.1,
P < 0.001), indicating the adequacy of the correlation matrix.
Two factors with eigenvalues higher than 1 accounted for a
cumulative variance of 57.68%. Nevertheless, parallel analysis
made it advisable for a single dimension to be retained, account-
ing for 48.58% of variance. The reliability estimate of the factor
was 0.89. All item loadings were above 0.50. The mean ﬁtted
residual was below the criterion (-0.05), though the RMSR was
slightly above the criterion (RMSR = 0.079).
Convergent validity results are shown in Table 4. Summary
indices of the PDQ-39 and SCOPA-PS correlated highly
(rS = 0.82). Correlation between SCOPA-PS and anxiety
(rS = 0.62) and depression (rS = 0.61) as measured by HADS, was
also high. In addition, correlations with SCOPA-MS (rS = 0.51)
and CISI-PD (rS = 0.57) were moderate, as they were with disease
stage (rS = 0.45) and duration (rS = 0.31). Correlation with the
CIRS-G (rS = 0.16) was weak. These results were consistent
across countries, as shown by Fisher’s Z test comparing
maximum and minimum correlation coefﬁcients per variable.
Table 1 Sociodemographic characteristics of Parkinson’s disease patients
Total (N = 331) Argentina (n = 61) Brazil (n = 127) Ecuador (n = 75) Paraguay (n = 68) P-value
Sex, % (n) ns
Male 57.70 (191) 54.10 (33) 57.48 (73) 62.67 (47) 55.88 (38)
Female 42.30 (140) 45.90 (28) 42.52 (54) 37.33 (28) 44.12 (30)
Mean age, years (SD) 64.68 (10.76) 63.10 (8.50) 63.00 (11.71) 68.01 (9.90) 65.57 (10.88) <0.05*
Years of education, mean (SD) 8.46 (5.49) 9.33 (4.55) 7.21 (6.00) 9.03 (4.96) 9.37 (5.51) <0.001
Marital status, % (n) ns
Married 66.77 (221) 72.13 (44) 64.57 (82) 64.00 (48) 69.12 (47)
Single 9.37 (31) 4.92 (3) 10.24 (13) 12.00 (9) 8.82 (6)
Widowed 12.69 (42) 13.11 (8) 14.17 (18) 13.33 (10) 8.82 (6)
Divorced 11.18 (37) 9.84 (6) 11.02 (14) 10.67 (8) 13.24 (9)
Municipality size <0.001
Rural 15.45 (51) 34.43 (21) 9.45 (12) 6.67 (5) 19.40 (13)
Medium 3.03 (10) 3.28 (2) 1.57 (2) 4.00 (3) 4.48 (3)
Urban 81.52 (269) 62.29 (38) 88.98 (113) 89.33 (67) 76.12 (51)
Disease duration, years (SD) 8.45 (6.04) 7.59 (4.90) 8.72 (5.51) 10.45 (8.28) 6.50 (4.02) <0.01
Hoehn and Yahr stage, % (n) <0.001
1 15.41 (51) 22.95 (14) 11.02 (14) 13.33 (10) 19.12 (13)
2 23.87 (79) 37.70 (23) 28.35 (36) 10.67 (8) 17.65 (12)
3 44.11 (146) 36.07 (22) 43.31 (55) 50.67 (38) 45.59 (31)
4 13.60 (45) 3.28 (2) 14.96 (19) 16.00 (12) 17.65 (12)
5 3.02 (10) 0.00 (0) 2.36 (3) 9.33 (7) 0.00 (0)
*Student’s t-test SD.
Kruskal–Wallis chi-square test.
ns, nonsigniﬁcant.
SCOPA-PS in four Latin American countries 387
Results were not signiﬁcantly different for all estimates excepting
bodily discomfort, cognitive status, and Hoehn and Yahr staging
(Fisher’s Z, P < 0.05) (Table 4).
Known-groups validity analyses showed that SCOPA-PS
scores increased gradually with HY and CISI-PD-based severity
levels, and with disease duration broken down by 5-year periods
(Kruskal–Wallis test, P < 0.0001).
Given that two pairs of relevant variables registered correla-
tions of over 0.40 (disease duration with HY, rS = 0.45; and
HADS-Dep with HADS-Anx, rS = 0.62), four regression models
were calculated, introducing and withdrawing one of the vari-
ables in each pair at a time (Table 5). The four regression models
(F = 80.15 - 106.25; R2: 0.42–0.49; all P < 0.0001) showed that
age, duration, HY, and HADS (both depression and anxiety) had
Table 2 Data quality, acceptability, and scale assumptions of the SCOPA-PS (n = 331)
% CS Min Max Mean Median SD % M-Me Item–total correlation
Item 1: work 99.11 0 3 1.46 1.00 0.96 15.42 0.58
Item 2: hobbies 99.11 0 3 1.36 1.00 1.02 11.84 0.58
Item 3: interacting with others 99.41 0 3 0.97 1.00 0.99 -1.09 0.69
Item 4: signiﬁcant others 99.11 0 3 0.80 1.00 0.96 -6.67 0.60
Item 5: sexuality 97.93 0 3 1.12 1.00 1.06 3.85 0.47
Item 6: staying at home 98.82 0 3 1.40 1.00 1.11 13.30 0.58
Item 7: help 99.11 0 3 1.13 1.00 1.04 4.18 0.61
Item 8: lonely 99.41 0 3 1.05 1.00 1.03 1.59 0.62
Item 9: conversation 98.82 0 3 1.05 1.00 1.01 1.55 0.71
Item 10: embarrassment 99.11 0 3 1.10 1.00 1.10 3.48 0.43
Item 11: future 99.11 0 3 1.68 2.00 1.04 -10.68 0.52
Total 97.93* 0 100 39.83 36.36 22.84 3.47
*n = 331/338.
Theoretical and empirical range are coincident in all items.
% CS, percentage of full computable scores; % M-Me, percentage of maximum score attributable to mean-median differences; max., maximum; min., minimum; SCOPA-PS, Scales for Outcomes
in Parkinson’s Disease-Psychosocial.
Table 3 Reliability and precision estimates of SCOPA-PS by country
Total (N = 331) Argentina (n = 61) Brazil (n = 127) Ecuador (n = 75) Paraguay (n = 68)
Cronbach’s alpha 0.87 0.92 0.86 0.87 0.86
Item homogeneity index 0.38 0.49 0.37 0.38 0.37
Standard error of measurement (upper 95% CI) 8.24 (16.14) 6.83 (13.38) 8.68 (17.02) 7.60 (14.89) 8.03 (15.75)
SD/2 11.42 12.07 11.61 10.54 10.74
95%CI, 95% conﬁdence interval; SCOPA-PS, Scales for Outcomes in Parkinson’s Disease-Psychosocial.
Table 4 Convergent validity of SCOPA-PS (Spearman’s rS)
Total (N = 331) Argentina (n = 61) Brazil (n = 127) Ecuador (n = 75) Paraguay (n = 68)
PDQ-39
Mobility 0.71 0.73 0.68 0.66 0.75
Activities of daily living 0.64 0.63 0.53 0.69 0.68
Emotional well-being 0.70 0.73 0.65 0.66 0.76
Stigma 0.51 0.63 0.50 0.53 0.44
Social support 0.59 0.54 0.64 0.57 0.45
Cognition 0.48 0.46 0.39 0.57 0.46
Communication 0.67 0.65 0.61 0.74 0.57
Bodily discomfort 0.42 0.52 0.41 0.45 0.17†
Summary index 0.82 0.85 0.80 0.78 0.83
SCOPA-Motor
Motor impairment 0.43 0.33 0.45 0.54 0.32
Activities of daily living 0.51 0.45 0.46 0.60 0.47
Motor complication 0.40 0.35 0.35 0.57 0.39
Total 0.51 0.43 0.51 0.59 0.42
CISI-PD
Motor signs 0.53 0.57 0.51 0.53 0.40
Disability 0.56 0.55 0.51 0.63 0.48
Motor complications 0.45 0.40 0.43 0.56 0.43
Cognitive status 0.36 0.29* 0.37 0.50 0.17†
Total 0.57 0.52 0.54 0.62 0.52
HADS
Depression 0.61 0.62 0.69 0.63 0.58
Anxiety 0.62 0.63 0.62 0.58 0.57
Hoehn and Yahr staging 0.45 0.28* 0.42 0.61 0.47
Disease duration (years) 0.31 0.22† 0.26 0.36 0.32
All P < 0.01, except *P < 0.05 and †nonsigniﬁcant.
CISI-PD,Clinical Impression of Severity Index for Parkinson’s Disease;HADS,HospitalAnxiety and Depression Scale; PDQ-39, Parkinson’s Disease Questionnaire-39 items; SCOPA-Motor, Scales
for Outcomes in Parkinson’s Disease-Motor; SCOPA-PS, Scales for Outcomes in Parkinson’s Disease-Psychosocial.
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an independent effect on psychosocial adjustment (SCOPA-PS)
(Table 5).
The SEM was 8.24 (upper 95% CI = 16.14). Precision by
country ranged from 6.83 (95% CI 13.38) to 8.68 (95% CI
17.02) (Table 3).
Discussion
According to our results, the psychometric properties of the
SCOPA-PS are consistent with the ﬁndings of previous studies
[8,10] (see Table 6 for comparison). It should be noted that the
present study doubles the sample size of previous surveys and is
the ﬁrst to include a signiﬁcant number of severe PD cases. In
addition, it is also the ﬁrst to be conducted in an international
setting and to explore some new features of the scale (speciﬁcally,
item homogeneity, content validity, and factor structure).
In line with previous studies [8,10], data quality indices were
above the standard threshold for full-computable data to be
considered acceptable, with the single exception of item 5 (sexu-
ality). Although most patients are generally assumed to be reluc-
tant to answer this question, the data quality of the scale could
nevertheless be improved by an additional instruction as to when
this item should be administered. Our data suggest that in cases
where only individuals with known partners are considered, the
rate of missing values ﬁts the criterion.
Scale acceptability proved satisfactory as assessed by the dif-
ference between observed and possible ranges, score variation
attributable to mean-median differences, absence of ﬂoor and
ceiling effects, and skewness according to standard criteria.
Scaling assumptions were likewise appropriate according to the
item–total correlation criterion. The internal consistency of the
scale was adequate and consistent with previously reported values
[8,10], and when approached via item homogeneity, internal
consistency again proved to be above the suggested threshold. The
content validity index suggests that the scale is highly relevant and
concise, though qualitative assessment by the panel of experts did
raise a few minor drafting issues.
Exploratory factor analysis and parallel analysis suggested a
one-factor solution, which strengthens the scale’s construct valid-
ity. Insofar as construct convergent validity was concerned, our
results largely supported the hypotheses posed, inasmuch as
SCOPA-PS displayed strong associations with HRQoL, depres-
sion, and anxiety, and moderate associations with PD symptoms,
PD staging, and disease duration. These results mimic those of
the original study, which also reported high convergent validity
between PDQ-39, HADS-Anx, and HADS-Dep, and SCOPA-PS.
Nevertheless, the study by Carod-Artal et al. [8] reported a mod-
erate association with depression and anxiety, a fact that may be
attributable to differential distribution of PD severity in their
sample (Table 6).
Construct validity was additionally supported by known-
groups analyses, which demonstrated gradual and signiﬁcant
reductions in psychosocial functioning (i.e., an increase in
SCOPA-PS scores) with longer disease duration and higher
severity categories. This ﬁnding is in line with the discriminative
Table 5 Regression models for SCOPA-PS scores
SCOPA-PS b SE 95%CI P-value
Model 1
Depression (HADS) 0.50 0.23 2.17 3.08 <0.001
Hoehn and Yahr staging 0.30 1.05 4.76 8.88 <0.001
Age (years) -0.17 0.08 -0.54 -0.19 <0.001
Model 2
Anxiety (HADS) 0.50 0.22 2.23 3.09 <0.001
Hoehn and Yahr 0.37 0.97 6.46 10.27 <0.001
Age (years) -0.16 0.09 -0.51 -0.17 <0.001
Model 3
Depression (HADS) 0.58 0.23 2.61 3.51 <0.001
Disease duration 0.16 0.17 0.28 0.94 <0.001
Age (years) -0.13 0.91 -0.46 -0.10 0.002
Model 4
Anxiety (HADS) 0.58 0.23 2.63 3.53 <0.001
Disease duration 0.19 0.17 0.40 1.05 <0.001
Age (years) -0.10 0.92 -0.40 -0.04 0.018
Sex, years of education,marital status,municipality size and illness severity (Cumulative Illness
Rating Scale Geriatric version) were included in all models. Only signiﬁcant predictors are
presented on the table.
b, Standardized beta coefﬁcient; 95%CI, 95% conﬁdence interval;HADS,HospitalAnxiety and
Depression Scale; SCOPA-PS, Scales for Outcomes in Parkinson’s Disease-Psychosocial; SE,
standard error.
Table 6 Psychometric properties of SCOPA-PS across validation studies
Marinus et al. 2003 [10] (n = 177) Carod-Artal et al. 2007 [8] (n = 144) Present study (n = 331)
Age (SD) 65.2 (11.10) 61.9 (11.10) 64.68 (10.76)
Disease duration (SD) 9.4 (5.60) 6.6 (3.80) 8.45 (6.04)
Hoehn and Yahr stage, % (n)
Hoehn and Yahr 1, 2 41.80 (74) 65.86 (95) 39.28 (130)
Hoehn and Yahr 3 39.50 (70) 22.14 (31) 44.11 (146)
Hoehn and Yahr 4, 5 18.60 (33) 12.86 (18) 16.62 (55)
Data quality
Item missing <5% <5% (item 5: 19.4%) <5% (item 5: 9.87%)
Floor/ceiling effects (%) — 1.40:0.70 0.91:0.91
Scale assumptions
Item–total correlation 0.24–0.67 0.44–0.73 0.43–0.71
Reliability
Cronbach’s alpha 0.83 0.84 0.87
Test–retest reliability 0.85 0.71 —
Precision
SEM (95% CI) 6.77 (13.26) 11.84 (23.20) 8.24 (16.14)
Validity
HADS-Anx 0.61 0.50 0.62
HADS-Dep 0.62 0.47 0.61
PDQ-39 0.82 0.73 0.82
HY* <0.001 0.007 <0.0001
*Discriminative analysis of Hoehn and Yahr (HY) staging (P-value).
95%CI, 95% conﬁdence interval; HADS, Hospital Anxiety and Depression Scale; PDQ-39, Parkinson’s Disease Questionnaire-39 items; SCOPA-PS, Scales for Outcomes in Parkinson’s
Disease-Psychosocial; SEM, standard error of measurement.
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analysis reported in the Brazilian study [8]. Finally, regression
analyses showed that depression, anxiety, and HY were the vari-
ables that accounted for most SCOPA-PS scoring variability
(Table 5).
The precision of the scale proved satisfactory, with the SEM
value being below the suggested criterion (SD/2). Moreover, the
SEM reported in our study was similar to that reported by the
original authors and considerably lower than that reported by
Carod-Artal et al. [8] (Table 6). Taking into account the SEM
values obtained from the three studies available, one could con-
clude that a change of 7 to 12 (around 10%) in the SCOPA-PS
summary index could be considered a real change and a
minimum important difference [35,38].
In some aspects, the study’s limitations are mainly related to
the sample’s variability among the participant countries. For
instance, most HY 5 participants came from Ecuador, while
Argentinean participants tended to be concentrated in HY stages
1 through 3. In addition, participants from Argentina tended to
live in rural areas more frequently than participants from other
countries did. It could be postulated that these differences may be
connected with the high levels of reliability and precision showed
by Argentinean participants. It could be argued that respondents
at low PD stages are more reliable in reporting their own psy-
chosocial functioning, which is consistent with better cognitive
functioning at early PD stages [39]. As a matter of fact,
Argentinean patients scored signiﬁcantly better in the CISI-PD
cognitive status domain (0.48 vs. 1.00–1.76, Kruskal–Wallis,
P < 0.0001). On the other hand, the removal of rural residents
did not alter their average SCOPA-PS score as it has been found
in other countries [40]. Finally, the high precision and reliability
in Argentineans may rather be a byproduct of their lower
SCOPA-PS score (34.53 vs. 35.00–43.67) as the scale seems to be
more internally consistent in the lower half score range than in
the higher (Cronbach alpha, 0.67 vs. 0.55). Although sample
variability may limit the internal validity of the study, it favors its
external validity. Test–retest reliability and responsiveness of the
measure were not assessed.
In summary, the tested Latin American versions of the
SCOPA-PS are reliable and valid for assessing psychosocial
adjustment among patients with mild, moderate, and severe PD.
Source of ﬁnancial support: No funding was received.
Supporting information for this article can be found at: http://
www.ispor.org/publications/value/ViHsupplementary.asp
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